NCT07283679 2026-04-20
Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Affiliated Hospital of Nantong University
TORL Biotherapeutics, LLC
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Nanjing IASO Biotechnology Co., Ltd.